Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
StaatusValmis
Sponsorid
Savino M. Di Stasi
Kaastöötajad
University of Bari

Märksõnad

Abstraktne

Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity. We want to evaluate the effects of intravesical Baobab oil in patients with BCG-induced lower urinary tract symptoms.

Kirjeldus

After complete transurethral resection of primary high risk non-muscle invasive bladder tumors (stage pTa, pT1, carcinoma in situ and high grade urothelial carcinoma), patients on induction course of intravesical BCG with lower urinary tract symptoms unresponsive to standard therapies are enrolled. The patients supply written informed consent to a document describing the investigational nature of the protocol.

Induction treatment consists of an initial 6 intravesical BCG treatments at weekly interval commencing approximately 3 weeks after transurethral resection procedures. The BCG instillation consisted of 81 mg wet weight (10•2±9•0 x 108 colony-forming units) BCG Connaught substrain. Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter.

During BCG treatment patients with persistent lower urinary tract symptoms unresponsive to standard therapies (anticholinergics, alpha-blockers, antibiotics, analgesics and anti-inflammatory drugs) are treated with an intravesical instillation of 50 ml sterile Baobab natural oil (Baotrophic, Physion Srl, Mirandola, Italy). After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.

Lower urinary tract symptoms are self-recorded by the patients before and after each baobab oil instillation and classified by the investigator according to a classification grid considering account duration and intensity. The classification of symptoms is class 0= none, class I = mild, class II = moderate, and class III = severe, according to severity. Local adverse events are cystitis, nocturia, pollakiuria, micturition urgency, micturition burning, stress urinary incontinence, dysuria, hematuria, pelvic pain, and perineal pain. The outcome measures are analyzed before and every day for one week after treatment. All patients are assessed for safety.

Kuupäevad

Viimati kinnitatud: 08/31/2013
Esmalt esitatud: 09/01/2013
Hinnanguline registreerumine on esitatud: 09/04/2013
Esmalt postitatud: 09/10/2013
Viimane värskendus on esitatud: 09/04/2013
Viimati värskendus postitatud: 09/10/2013
Õppe tegelik alguskuupäev: 12/31/2011
Eeldatav esmane lõpetamise kuupäev: 05/31/2013
Eeldatav uuringu lõpetamise kuupäev: 05/31/2013

Seisund või haigus

Superficial Bladder Cancer
Lower Urinary Tract Symptoms

Sekkumine / ravi

Device: Intravesical baobab oil

Faas

Faas 1/Faas 2

Käerühmad

ArmSekkumine / ravi
Experimental: Intravesical baobab oil
Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
Device: Intravesical baobab oil
Intravesical baobab oil

Abikõlblikkuse kriteeriumid

Õppimiseks sobivad vanused 18 Years To 18 Years
Uuringuks kõlblikud soodAll
Võtab vastu tervislikke vabatahtlikkeJah
Kriteeriumid

Inclusion Criteria:

- Age 18 years or older

- Complete transurethral resection of primary histologically proven high risk urothelial non-muscle invasive bladder tumors: high grade (G3,) stage pTa, pT1, and carcinoma in situ (pTis

- Intravesical BCG treatment

- Adequate bone marrow reserve (ie, white-blood-cell count ≥4000 x106 cells/L and platelet count

≥120 x 109/L

- Normal renal function (function (ie, serum creatinine ≤123•76 µmol/L)

- normal liver function ((ie, serum glutamic-oxaloacetic transaminase ≤42 U/L, serum glutamic-pyruvic transaminase ≤48 U/L, and total bilirubin ≤22•23 µmol/L)

- Karnofsky performance score of 50 to 100

Exclusion Criteria:

- Previous intravesical treatment with chemotherapeutic and immunotherapeutic drugs

- Previous or concomitant urothelial carcinoma of the upper urinary tract and urethra, or both

- Previous muscle-invasive (ie, stage T2 or higher) urothelia carcinoma of the bladder

- Known allergy to baobab oil

- Bladder capacity less than 200 mL

- Untreated urinary-tract infection

- Severe systemic infection (ie, sepsis)

- Urethral strictures that would prevent endoscopic procedures and catheterisation

- Disease of upper urinary tract (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures at risk

- Previous radiotherapy to the pelvis;

- Other concurrent chemotherapy;

- Treatment with radiotherapy-response or biological-response modifiers;

- Other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma);

- Pregnancy or nursing;

- Psychological, familial, sociological, or geographical factors that would preclude study participation.

Tulemus

Esmased tulemusnäitajad

1. Quantitative symptom score questionnaire [36 months]

A quantitative symptom score questionnaire is completed by the patients before treatment to establish baseline symptoms and daily during the following 7 days after treatment. The questionnaire is designed to evaluate 10 lower urinary tract symptoms (cystitis, nocturia, pollakiuria, micturition urgency, micturition burning, stress urinary incontinence, dysuria, hematuria, pelvic pain, and perineal pain. Most symptoms are scored on a 0 to 3-point scale, corresponding to none/mild/moderate/severe.

Sekundaarsed tulemusmõõdud

1. Baobab oil toxicity [36 months]

All patients are assessed for safety or allergy to intravesical baobab oil

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge